Strategies to decrease taxanes toxicities in the adjuvant treatment of early breast cancer

Shou-Ching Tang

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Taxanes are tubulin-targeting agents that are highly active in the treatment of breast cancer. The lack of cross-resistance and limited overlapping toxicities of taxanes with other agents, such as anthracycline, made it possible to incorporate them in the adjuvant treatment of early breast cancer. When used alone or in combination with other cytotoxic agents, taxanes significantly improved response rate, time to progression, disease-free and in some trials over-all survival in patients with advanced or metastatic breast cancer. Mature data are now emerging from the early randomized clinical trials that consistently demonstrate a clear survival benefit of taxanes when combined with anthracycline. However, increased toxicities, especially hematological toxicities, were also observed. Various strategies to decrease the taxanes toxicities have been explored, including appropriate dosing and scheduling to optimize the therapeutic index, sequential rather than concurrent use of anthracycline and taxanes, the use of growth factor support and the removal of anthracycline, with encouraging results. The development of novel taxanes with less toxicities and use of molecular markers to target patients with taxane-responsive tumors are in early clinical trials. This review focuses on safety issues of taxanes in the adjuvant treatment of early breast cancer. Strategies to reduce the taxane toxicity and future direction of taxane research in early breast cancer will be discussed.

Original languageEnglish (US)
Pages (from-to)206-214
Number of pages9
JournalCancer Investigation
Volume27
Issue number2
DOIs
StatePublished - Feb 1 2009

Fingerprint

Taxoids
Breast Neoplasms
Anthracyclines
Therapeutics
Survival
Cytotoxins
Tubulin
Disease Progression
Intercellular Signaling Peptides and Proteins
Randomized Controlled Trials
Clinical Trials
Safety

Keywords

  • Anthracycline
  • Docetaxel
  • Early Breast cancer
  • Paclitaxel
  • Quality of life
  • Taxanes
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Strategies to decrease taxanes toxicities in the adjuvant treatment of early breast cancer. / Tang, Shou-Ching.

In: Cancer Investigation, Vol. 27, No. 2, 01.02.2009, p. 206-214.

Research output: Contribution to journalReview article

@article{11cc1862132a43b2859e700f193482b8,
title = "Strategies to decrease taxanes toxicities in the adjuvant treatment of early breast cancer",
abstract = "Taxanes are tubulin-targeting agents that are highly active in the treatment of breast cancer. The lack of cross-resistance and limited overlapping toxicities of taxanes with other agents, such as anthracycline, made it possible to incorporate them in the adjuvant treatment of early breast cancer. When used alone or in combination with other cytotoxic agents, taxanes significantly improved response rate, time to progression, disease-free and in some trials over-all survival in patients with advanced or metastatic breast cancer. Mature data are now emerging from the early randomized clinical trials that consistently demonstrate a clear survival benefit of taxanes when combined with anthracycline. However, increased toxicities, especially hematological toxicities, were also observed. Various strategies to decrease the taxanes toxicities have been explored, including appropriate dosing and scheduling to optimize the therapeutic index, sequential rather than concurrent use of anthracycline and taxanes, the use of growth factor support and the removal of anthracycline, with encouraging results. The development of novel taxanes with less toxicities and use of molecular markers to target patients with taxane-responsive tumors are in early clinical trials. This review focuses on safety issues of taxanes in the adjuvant treatment of early breast cancer. Strategies to reduce the taxane toxicity and future direction of taxane research in early breast cancer will be discussed.",
keywords = "Anthracycline, Docetaxel, Early Breast cancer, Paclitaxel, Quality of life, Taxanes, Toxicity",
author = "Shou-Ching Tang",
year = "2009",
month = "2",
day = "1",
doi = "10.1080/07357900802178520",
language = "English (US)",
volume = "27",
pages = "206--214",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Strategies to decrease taxanes toxicities in the adjuvant treatment of early breast cancer

AU - Tang, Shou-Ching

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Taxanes are tubulin-targeting agents that are highly active in the treatment of breast cancer. The lack of cross-resistance and limited overlapping toxicities of taxanes with other agents, such as anthracycline, made it possible to incorporate them in the adjuvant treatment of early breast cancer. When used alone or in combination with other cytotoxic agents, taxanes significantly improved response rate, time to progression, disease-free and in some trials over-all survival in patients with advanced or metastatic breast cancer. Mature data are now emerging from the early randomized clinical trials that consistently demonstrate a clear survival benefit of taxanes when combined with anthracycline. However, increased toxicities, especially hematological toxicities, were also observed. Various strategies to decrease the taxanes toxicities have been explored, including appropriate dosing and scheduling to optimize the therapeutic index, sequential rather than concurrent use of anthracycline and taxanes, the use of growth factor support and the removal of anthracycline, with encouraging results. The development of novel taxanes with less toxicities and use of molecular markers to target patients with taxane-responsive tumors are in early clinical trials. This review focuses on safety issues of taxanes in the adjuvant treatment of early breast cancer. Strategies to reduce the taxane toxicity and future direction of taxane research in early breast cancer will be discussed.

AB - Taxanes are tubulin-targeting agents that are highly active in the treatment of breast cancer. The lack of cross-resistance and limited overlapping toxicities of taxanes with other agents, such as anthracycline, made it possible to incorporate them in the adjuvant treatment of early breast cancer. When used alone or in combination with other cytotoxic agents, taxanes significantly improved response rate, time to progression, disease-free and in some trials over-all survival in patients with advanced or metastatic breast cancer. Mature data are now emerging from the early randomized clinical trials that consistently demonstrate a clear survival benefit of taxanes when combined with anthracycline. However, increased toxicities, especially hematological toxicities, were also observed. Various strategies to decrease the taxanes toxicities have been explored, including appropriate dosing and scheduling to optimize the therapeutic index, sequential rather than concurrent use of anthracycline and taxanes, the use of growth factor support and the removal of anthracycline, with encouraging results. The development of novel taxanes with less toxicities and use of molecular markers to target patients with taxane-responsive tumors are in early clinical trials. This review focuses on safety issues of taxanes in the adjuvant treatment of early breast cancer. Strategies to reduce the taxane toxicity and future direction of taxane research in early breast cancer will be discussed.

KW - Anthracycline

KW - Docetaxel

KW - Early Breast cancer

KW - Paclitaxel

KW - Quality of life

KW - Taxanes

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=60849121122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60849121122&partnerID=8YFLogxK

U2 - 10.1080/07357900802178520

DO - 10.1080/07357900802178520

M3 - Review article

VL - 27

SP - 206

EP - 214

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 2

ER -